PPIs create dependency: the drug 'manufactures the disease it claims to treat', so that a short course for a passing complaint turns into chronic dependence and one 'cannot stop'.

Original statement

لكنّ المفتاح الذي يفسّر الإدمان الذي يصفه د. ضياء هو دراسة ريمر (Gastroenterology 2009): 120 متطوعاً صحيحاً تماماً، أُعطوا إيزوميبرازول 40 ملغ ثمانية أسابيع. بعد التوقف، 44% منهم ظهرت لديهم حرقة وارتداد لأول مرة في حياتهم، مقابل 15% للغفل. الدواء يخلق المرض الذي يدّعي علاجه. هذا هو الفخّ الذي يحذّر منه: ابدأ نكسيم لشكوى عابرة، فلا تستطيع التوقف.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

PPIs create dependency: the drug 'manufactures the disease it claims to treat', so that a short course for a passing complaint turns into chronic dependence and one 'cannot stop'.

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com); not verified as Elawady's own words

Origin

https://eltayebat.com/rule/acid-blockers/

Attribution uncertainty

Written by the archive operators; study selection is the archive's, not necessarily Elawady's.

Claimed mechanism

Rebound acid hypersecretion.

Claimed health effect

Lifelong dependence.

Population concerned

PPI users.

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

PPIs create an inescapable dependence.

2. What is demonstrably correct?

Rebound symptoms can make stopping harder and may contribute to unnecessary long-term use (a hypothesis stated in Lødrup 2013).

3. What is wrong or exaggerated?

'Cannot stop' is not supported: guidelines (Farrell 2017; AGA 2022) describe successful dose reduction, on-demand use and discontinuation in suitable patients, by tapering or abrupt stop. 'Addiction' is not the right concept: there is no craving or compulsive use.

4. What remains unclear?

How often rebound is the main reason for long-term use in practice is not known.

5. Which studies support it?

A-PPI-14 (mechanism only).

6. Which studies contradict it?

Farrell 2017 (I-PPI-05), AGA 2022 (I-PPI-04), Lødrup 2013 (I-PPI-06).

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

People who want to stop a PPI should do so with their doctor, expecting a few weeks of possible rebound; those with Barrett's oesophagus, severe oesophagitis or bleeding risk should not stop without specialist advice.

Assessment details

Rationale for certainty of evidence

Rebound is real (C-PPI-06) but transient; deprescribing guidelines based on trials show that many patients without a continuing indication can reduce or stop PPIs; no evidence was found of pharmacological addiction.

Source quality

Archive editorial extrapolation from one volunteer RCT.

Regional transferability

High.

Individual exceptions

Patients with ongoing reflux disease may genuinely need long-term therapy; this is not dependence.

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

Stopping an acid blocker can cause a few weeks of extra heartburn. That makes stopping uncomfortable, but it does not mean that people cannot stop. Guidelines explain how to reduce or stop these drugs step by step, and many people manage to do so. People with certain conditions, however, need to keep taking them.

Studies on this claim

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Mostly false Overstated: rebound is temporary and PPIs can usually be reduced or stopped when no longer indicated.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.. Farrell B et al.. Can Fam Physician 2017 · PMID 28500192
2. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247
3. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.. Lødrup AB et al.. Scand J Gastroenterol 2013 · PMID 23311977 · DOI 10.3109/00365521.2012.746395
4. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.. Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058